Formed in 2015, HLS Therapeutics ("HLS") is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets.
HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas.
HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.
Mr. Greg Gubitz
Chief Executive Officer
10 Carlson Court, Suite 701
Ontario, M9W 6L2